1. Pink Sheet
  2. >>Geography
  3. >>Europe

In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims

Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.

Prestige Brands Holdings Inc.’s $750 million acquisition of Insight Pharmaceuticals Corp. gives the Tarrytown, N.Y., firm a leading platform in feminine care and brings it closer to its goal of becoming a $1 billion OTC company, the firm said April 25. The new feminine care portfolio “is anchored by Monistat, Prestige’s first $100 million brand and the yeast infection treatment recommended by most doctors, said Prestige CEO Matthew Mannelly. The feminine care portfolio also includes Uristat urinary health products and e.p.t. at home pregnancy test. The deal also brings Prestige iconic cough lozenges Sucrets and Cepastat, the pain reliever Anacin, Chooz antacid gum and other brands. The deal follows the April 15 acquisition of Hydralyte drink brand, expected to add $300 million in revenues. The Insight acquisition should add $800 million in revenue, Prestige said. Insight substantially expanded its business in 2011 with acquisitions of women’s health care brands from McNeil Consumer HealthcareAlso see "Insight Acquires Monistat In Third Deal With McNeil For Women’s OTC Drugs" - Pink Sheet, 5 September, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

CSL Makes Landmark National-Level Pay-For-Performance Deal In Germany For Hemgenix

 
• By Francesca Bruce

A blanket pricing agreement CSL has formed with German health insurers for the gene therapy, Hemgenix, makes the cost of treatment budget-neutral compared to traditional treatment.

New Carbon Monitoring Initiative Could Help Future Proof Clinical Research

 
• By Francesca Bruce

A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.

Major Analysis To Help MHRA Fill Gaps In UK Clinical Trials Landscape

 
• By Vibha Sharma

A first-of-its-kind review of clinical trial applications submitted to the UK medicines regulator, the MHRA, shows there is a concentration of research in certain disease areas and identifies opportunities to enhance the representation of specific patient groups.

New Medicines Pricing Proposals Would Mean More Uncertainty For Spanish Supply Chains

 
• By Francesca Bruce

Proposals to reform Spain’s reference pricing system are out of whack with the national pharmaceutical strategy published in December, six industry associations have warned.

More from Geography

GLP-1 Drug Coverage Growing For Obesity In Medicaid, But Only For Diabetes In Medicare

 
• By Cathy Kelly

Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.

US FDA Allows Telework For Reviewers As Companies Detail Layoff-Related Problems

 
• By Derrick Gingery

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.

Kennedy’s Comments On Novavax Delay Scientifically, Legally Inaccurate, Experts Say

 
• By Sarah Karlin-Smith

The HHS Secretary publicly acknowledged the unusual delay of Novavax's COVID-19 vaccine licensure, but his justification was neither scientifically accurate nor legally justifiable, experts said.